A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

BrainXell today announced the launch of its human induced pluripotent stem cell (iPSC)-derived sensory neurons, a scalable human cellular platform engineered to support reproducible functional studies ...

Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients ...

Japan’s health ministry has granted conditional, time-limited authorization for two stem-cell therapies derived from induced pluripotent stem (iPS) cells, endorsing them for use based on early safety ...

Japan approves world-first iPS cell therapies for heart failure, Parkinsons Conditional approvals speed Japans first iPS ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell ...

VANCOUVER, BC and TOKYO, March 3, 2026 /CNW/ - The International Society for Cell & Gene Therapy (ISCT), the translation-focused global community of cell and gene therapy experts and the ...

DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...